In one of the studies, the proliferation of cancer cells with K-Ras mutations was inhibited by the combination of an allosteric inhibitor of Akt (MK-2206) and several RTK inhibitors (jnj38877605, Lapatinib, OSI-906) [133]. Here, KRAS is linked to cancer.